Amrinone is a bipyridine compound with characteristic effects on the force-velocity relationship of fast skeletal muscle, including a reduction in the maximum shortening velocity and increased maximum isometric force. Here we performed experiments to elucidate the molecular mechanisms for these effects, with the additional aim to gain insight into the molecular mechanisms underlying the force-velocity relationship.
In vitro motility assays established that amrinone reduces the sliding velocity of heavy meromyosin-propelled actin filaments by 30% at different ionic strengths of the assay solution. Stopped-flow studies of myofibrils, heavy meromyosin and myosin subfragment 1, showed that the effects on sliding speed were not because of a reduced rate of ATP-induced actomyosin dissociation because the rate of this process was increased by amrinone. Moreover, optical tweezers studies could not detect any amrinone-induced changes in the working stroke length. In contrast, the ADP affinity of acto-heavy meromyosin was increased about 2-fold by 1 m
m amrinone. Similar effects were not observed for acto-subfragment 1. Together with the other findings, this suggests that the amrinone-induced reduction in sliding velocity is attributed to inhibition of a strain-dependent ADP release step. Modeling results show that such an effect may account for the amrinone-induced changes of the force-velocity relationship. The data emphasize the importance of the rate of a strain-dependent ADP release step in influencing the maximum sliding velocity in fast skeletal muscle. The data also lead us to discuss the possible importance of cooperative interactions between the two myosin heads in muscle contraction.Muscle contraction, as well as several other aspects of cell motility, results from cyclic interactions between myosin II motors and actin filaments. These force-generating interactions are driven by the hydrolysis of ATP at the myosin active site as outlined in (
1–
3). In the absence of actin, the P
i and ADP release steps (
k4 and
k5) are rate-limiting for the entire cycle at high (>12 °C) and low temperatures, respectively (
4–
6). In the presence of actin, the rate of P
i release increases significantly, and the overall cycle is accelerated more than 2 orders of magnitude. The sliding velocity of myosin-propelled motors is generally believed to be rate-limited by actomyosin dissociation (rate constant
k′
5,
k′
6, or
k′
2 in ) (
7). Alternatively, some studies (
8,
9) have suggested that the sliding velocity is determined by the fraction of myosin heads in the weak-binding states, AM
4 ATP and AM ADP P
i. However, it is worth emphasizing that
KT is very low under physiological conditions (
1,
3) with low population of these states. For the same reason, the rate of dissociation of the AM complex is governed by
K′
1 and
k′
2.
Open in a separate windowSimplified kinetics scheme for MgATP turnover by myosin (
lower row) and actomyosin (
upper row). Inorganic phosphate is denoted by
Pi; MgATP is denoted by
ATP, and MgADP is denoted by
ADP; myosin is denoted by
M. The states AM*ADP and AM ADP correspond to myosin heads with their nucleotide binding pocket in a partially closed and open conformation, respectively (
7,
52). Rate constants are indicated by
lowercase letters (rightward transitions,
k2 −
k5 and
k′
2 −
k′
5, or leftward transitions,
k−2 −
k−5 and
k′
−2 −
k′
−5) and equilibrium constants by
uppercase letters (
K1,
K′
1,
KT,
K3,
K′
3,
K6,
k′
6, and
KDP). The equilibrium constants are association constants except for simple bimolecular reactions where they are defined as
ki/
k−i.For the study of contractile mechanisms in both muscle and other types of cells, drugs may be useful as pharmacological tools affecting different transitions or states in the force-generating cycle. Whereas the use of drugs as tools may be less specific than site-directed mutagenesis, it also has advantages. The motor protein function may be studied
in vivo, with maintained ordering of the protein components,
e.g. as in the muscle sarcomere, allowing more insight into the relationship between specific molecular events and contractile properties of muscle. A drug that has been used quite extensively in this context is butanedione monoxime. The usefulness of this drug is based on firm characterization of its effect on actomyosin function on the molecular level (
3,
10–
13). More recently other drugs, like
N-benzyl-
p-toluene sulfonamide (
14,
15) and blebbistatin (
16), have been found to affect myosin function, and their effects at the molecular level have also been elucidated in some detail (
14,
15,
17,
18). Both these drugs appear to affect the actomyosin interaction in a similar way as butanedione monoxime by inhibiting a step before (or very early in) the myosin power stroke, leading to the inhibition of actomyosin cross-bridge formation and force production.In contrast to the reduced isometric force, caused by the above mentioned drugs, the bipyridine compound amrinone (
A) has been found to increase the isometric force production of fast intact skeletal muscles of the frog (
19,
20) and mouse (
21) and also of fast (but much less slow) skinned muscle fibers of the rat (
22). In all the fast myosin preparations, the effect of about 1 m
m amrinone on isometric force was associated with characteristic changes of the force-velocity relationship (
B), including a reduced maximum velocity of shortening (
19–
22) and a reduced curvature of the force-velocity relationship (
19–
22). The latter effect was accompanied (
20,
21) by a less pronounced deviation of the force-velocity relationship from the hyperbolic shape (
23) at high loads. There have been different interpretations of the drug effects. It has been proposed (
20–
22) that amrinone might competitively inhibit the MgATP binding by myosin. However, more recently, results from
in vitro motility assay experiments (
24) challenged this idea. These results showed that amrinone reduces the sliding velocity (
Vmax) at saturating MgATP concentrations but not at MgATP concentrations close to, or below, the
Km value for the hyperbolic relationship between MgATP concentration and sliding velocity. Such a combination of effects is consistent with a reduced MgADP release rate (
24) but not with competitive inhibition of substrate binding. However, effects of amrinone on the MgADP release rate have not been directly demonstrated. Additionally, in view of the uncertainty about what step actually determines the sliding velocity at saturating [MgATP] (see above and Refs.
7–
9), it is of interest to consider other possible drug effects that could account for the data of Klinth
et al. (
24). These include the following: 1) an increased drag force,
e.g. because of enhancement of weak actomyosin interactions; 2) a reduced step length; and 3) effects of the drug on the rate of MgATP-induced dissociation of actomyosin.
Open in a separate windowA, structure of amrinone.
B, experimental force-velocity data obtained in the presence (
filled symbols) and absence (
open symbols) of 1.1 m
m amrinone. The data, from intact single frog muscle fibers, were obtained at 2 °C and fitted by Hill''s (
42) hyperbola (
lines) for data truncated at 80% of the maximum isometric force.
Filled line, equation fitted to control data,
a/
P0* = 0.185;
P0*/
P0 = 1.196.
Dashed line, amrinone,
a/
P0* = 0.347;
P0*/
P0 = 1.009. Force-velocity data were obtained in collaboration with Professor K. A. P. Edman. Same data as in of Ref.
20. Note a decrease in maximum sliding velocity and curvature of the force-velocity relationship at low force, in response to amrinone. Also note that amrinone caused increased isometric force and a reduced deviation of the force-velocity relationship from the Hill''s hyperbola at high force. All changes of the force-velocity relationship were statistically significant (
20), and similar changes were later also observed in intact mouse muscle and skinned rat muscle fibers. Data in are published by agreement with Professor K. A. P. Edman.To differentiate between these hypotheses for the amrinone effects, and to gain more general insight into fundamental aspects of muscle function (
e.g. mechanisms underlying the force-velocity relationship), we here study the molecular effects of amrinone on fast skeletal muscle myosin preparations in the presence and absence of actin.
In vitro motility assay studies at different ionic strengths suggest that drag forces, caused by increased fraction of myosin heads in weak binding states, are not important for the effect of amrinone on sliding velocity. Likewise, optical tweezers studies showed no effect of the drug on the myosin step length. Finally, ideas that amrinone should reduce sliding velocity by reduced rate of MgATP-induced dissociation could be discarded because the drug actually increased the rate of this process. Instead, we found an amrinone-induced increase in the MgADP affinity of heavy meromyosin (HMM) in the presence of actin. Interestingly, similar effects of amrinone were
not observed using myosin S1. As discussed below, this result and other results point to an amrinone-induced reduction in the rate of a strain-dependent MgADP release step. Simulations, using a model modified from that of Edman
et al. (
25), support this proposed mechanism of action. The results are discussed in relation to fundamental mechanisms underlying the force-velocity relationship of fast skeletal muscle, including which step determines shortening velocity and the possible importance of inter-head cooperativity.
相似文献